Table 1.
2010 US Spending on Sample Chemotherapies for Cancer Treatment by On-Label and Off-Label Uses
| Chemotherapy | US Manufacturer | Market Launch Date | Total US Sales* ($M) | Estimated US Sales |
|||
|---|---|---|---|---|---|---|---|
| On-Label† ($M) | Off-Label ($M) | Off-Label, NCCN Supported ($M) | Off-Label, Other | ||||
| Docetaxel | sanofi-aventis US | May 1996 | 1,198 | 928 | 271 | 144 | 127 |
| Gemcitabine | Lilly | May 1996 | 780 | 250 | 530 | 273 | 257 |
| Rituximab | Genentech | Nov 1997 | 2,320 | 922 | 1,398 | 557 | 998 |
| Trastuzumab | Genentech | Sep 1998 | 1,538 | 1,523 | 15 | 15 | 0 |
| Bortezomib | Millennium Pharma/Takeda | May 2003 | 580 | 534 | 46 | 23 | 25 |
| Bevacizumab | Genentech | Feb 2004 | 3,100 | 1,158 | 1,942 | 837 | 768 |
| Cetuximab | ImClone/Lilly | Feb 2004 | 709 | 567 | 142 | 70.9 | 69 |
| Pemetrexed | Lilly | Feb 2004 | 992 | 913 | 79 | 10 | 68 |
| Azacitidine | Celgene | May 2004 | 292 | 237 | 55 | 38 | 18 |
| Paclitaxel albumin bound | Abraxis Bioscience/Celgene | Jan 2005 | 345 | 224 | 121 | 52 | 59 |
| Total annual revenue | 11,951 | 7,255 | 4,479 | 2,020 | 2,390 | ||
*
Total US Sales were provided by IMS Health National Sales Perspectives. Only sales of the drug for cancer treatment are reported. According the 2010 Genentech/Roche Annual Report to shareholders, rituximab total US Sales included 16% for the treatment of noncancer diagnoses. Noncancer sales for rituximab were excluded from those reported in the table.
†
Sales by on-label category were calculated for each drug by multiplying the percentage of use by on-label and off-label use estimated by total cancer-related annual sales.